Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

Incyte (NASDAQ:INCY) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Genmab has reported new outcomes from the Phase Ib/II EPCORE NHL-2 trial Arm 10 of T-cell engaging bispecific antibody, ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

InnoCare gets China NMPA approval for Minjuvi in combo with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma: Beijing, China Friday, May 23, 2025, 13:00 ...

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows ...

The most commonly used combo is nicknamed R-CHOP, and it is given with the goal of remission, which many can achieve with DLBCL. You get the R-CHOP regimen in cycles spaced three weeks apart.